The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Somaxon Pharmaceuticals Inc.  (SOMX) Trade Now »     Rate SOMX  -  Discuss SOMX  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
This is a micro-cap stock and may be a target of manipulation. Always do your research!

SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
73.0%
Top:
100.0%
Rate SOMX:



SOMX Analysis & Videos »


SOMX: Bull or Bear?

Hospitals, Regulatory Catalyst Index News: $SOMX $APPA $MDTH Graphic_rating_buy SOMX
Mikerun
73%
 -95.41%
in 810 days

<font> Shares of Somaxon Pharma (NASDAQ: SOMX) ($6.51, +65%) are soaring with heavy trading volume following news of FDA approval of its insomnia drug Silenor (doxepin). </font>

<font> AP Pharma (NASDAQ: APPA) is trading up by 20% at $1.87 ahead of an expected FDA decision today for APF530 (long-acting granisetron), which is a novel formulation of already approved ingredient (granisetron is currently marketed as Kytril) for the treatment of nausea. </font>

<> <font> Shares of cardiac hospital operator MedCath (NASDAQ: MDTH) are surging by 27% at $12.06 on a Deutsche Bank analys...
By  Mike Havrilla   (+1.04%  risk: moderate)  03/18/10 36 comments


Regulatory Catalyst Extreme Trades: $APPA, $APPY $ARIA, $CTIC, $SOMX Graphic_rating_buy SOMX
Mikerun
73%
 +58.88%
in 2 days
(closed on 03/18/10)
<> The actively managed HavRx Regulatory Catalyst Index tracks the performance of select companies which meet any of the following requirements: (1) pending new drug, biological agent, medical device, or diagnostic product applications at the FDA; (2) pending pivotal clinical trial results that are designed to support a new filing or resubmission for FDA marketing clearance; and (3) pending early stage clinical study results. Categories (1) and (2) will comprise two-third (67%) or greater of all index components while companies with pending early stage clinical trial results will comprise one...
By  Mike Havrilla   (+1.04%  risk: moderate)  03/16/10 5 comments


20 Extreme Trades on Pending FDA Decisions Graphic_rating_buy SOMX
Mikerun
73%
 +280.56%
in 268 days
(closed on 03/16/10)
<> Below are 20 extreme trades among companies with market caps under $500 million from the <font> BioMedReports.com FDA Calendar </font> (database includes 225 entries as of 6/21/09) which have pending FDA decisions for either new drug products or biological agents that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in <font> Extreme FDA and Clinical Trial Calendar Trades </font> , which are highlig...
By  Mike Havrilla   (+1.04%  risk: moderate)  06/21/09 21 comments


Get free stock alert for SOMX:
Your Email Address:


FDA Decision Calendar: Extreme Trades Graphic_rating_sell SOMX
Mikerun
73%
 +79.13%
in 42 days
(closed on 02/28/09)
FDA Decision Calendar: Extreme Trades
 
The table at my website link below includes an updated calendar of 78 expected FDA new product decisions with more detailed comments for each entry. Click here for a link to my previous FDA calendars and the list below highlights companies with pending decisions + market caps below $100M, making them ideal candidates for extreme trading opportunities.
 
 
<> BioDelivery Sciences (BDSI) – Onsolis approval is possible by mid-2009 and <><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
By  Mike Havrilla   (+1.04%  risk: moderate)  01/17/09 1 comment


FDA Decision Calendar: Extreme Trades Graphic_rating_buy SOMX
Mikerun
73%
 +0.00%
in 0 minute
(closed on 01/17/09)
FDA Decision Calendar: Extreme Trades
 
The table at my website link below includes an updated calendar of 78 expected FDA new product decisions with more detailed comments for each entry. Click here for a link to my previous FDA calendars and the list below highlights companies with pending decisions + market caps below $100M, making them ideal candidates for extreme trading opportunities.
 
 
<> BioDelivery Sciences (BDSI) – Onsolis approval is possible by mid-2009 and <><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
By  Mike Havrilla   (+1.04%  risk: moderate)  01/17/09 3 comments


Somaxon Upside is Tremendous Graphic_rating_buy SOMX
-93.03%
in 1489 days
Somaxon is currently in discussion with several interested parties for commercialization of the drug in early 2009.
By  Zacks.com   (-16.75%  risk: moderate)  05/07/08 Comment





People Bullish on SOMX

zvitrader
Analyst
N/A
about 1 year ago

bluetalon
Analyst
N/A
over 2 years ago

Dean_logo
the_dean
Analyst
N/A
over 2 years ago

Mikerun
Mike Havrilla
Principal
73%
over 2 years ago

450vampyr_avatar-med
supratrader
Principal
N/A
over 2 years ago


People Bearish on SOMX

damel4299
Analyst
N/A
about 1 year ago

jagwar
Analyst
N/A
over 2 years ago

ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.36% 531
2 Gerald Greene 18.14 +36.28% 286
3 stockmarketfunding.com 17.66 +23.07% 83
4 akiralegrand 13.47 +13.37% 69
5 anup2104 12.13 +132.16% 102


POPULAR STOCKS
Symbol Company Name Sentiment
DRYS DryShips Inc.
V Visa Inc
DELL Dell Inc
LEH Lehman Brothers Holdings Inc
WFC Wells Fargo & Company
INTC Intel Corp

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on SOMX


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About Somaxon Pharmaceuticals Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch